TUMOR MICROENVIRONMENT DYNAMICS: MOLECULAR AND GENETIC DETERMINANTS OF CANCER PROGRESSION AND THERAPY RESPONSE

Abstract

Malignant cells, stromal cells, immunological populations, extracellular matrix elements, and other signalling chemicals make up the tumour microenvironment (TME), a dynamic and intricate ecology that controls cancer initiation, development, metastasis, and treatment response.  There is growing evidence that the reciprocal interactions between tumour cells and the tumour microenvironment are critical in defining the course of the illness and the effectiveness of therapy. This review aims to recapitulate the molecular, genetic, epigenetic, and immunological determinants governing tumor microenvironment dynamics, emphasising their contributions to therapeutic resistance, the development of microenvironment-targeted therapy approaches, and the progression of cancer. A literature review was conducted using peer-reviewed articles published in high-impact scientific journals. Relevant studies addressing the molecular architecture of the tumor microenvironment, signaling pathways, immune regulation, tumor heterogeneity, therapeutic resistance, and an integrative picture of current knowledge was produced by critically analysing and synthesising developing technology. and future research directions. The evidence demonstrates that growth factor signalling, inflammatory pathways, hypoxia, metabolic reprogramming, genetic and epigenetic alterations, and extracellular vesicle-mediated communication alter the tumour microenvironment, encouraging tumour growth, metastasis, immune escape, and resistance to immunotherapy, chemotherapy, radiation, and targeted treatment. By enhancing biomarker identification and customised therapy decision making, emerging technologies including as single-cell multi-omics, spatial transcriptomics, artificial intelligence, organoid models, and liquid biopsy are boosting precision oncology. Targeting the tumor microenvironment alongside malignant cells offers significant opportunities to overcome therapeutic resistance and improve clinical outcomes. Integrating multi-omics technologies with precision medicine methods are anticipated to aid in the creation of individualised, long-lasting, and more potent cancer treatments.